We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Advaxis Inc (ADXS) USD0.001

Sell:$0.068 Buy:$0.068 Change: $0.0031 (4.78%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
Sell:$0.068
Buy:$0.068
Change: $0.0031 (4.78%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
Sell:$0.068
Buy:$0.068
Change: $0.0031 (4.78%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Advaxis, Inc. is a clinical-stage biotechnology company, which is focused on the development and commercialization of Listeria monocytogenes (Lm) technology antigen delivery products. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on single antigen and multiple antigen delivery products. The Company's pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. It has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.

Contact details

Address:
9 DEER PARK DRIVE, SUITE K-1
MONMOUTH JUNCTION
08852
United States
Telephone:
+1 (732) 5451590
Website:
https://www.advaxis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ADXS
ISIN:
US0076243072
Market cap:
$10.06 million
Shares in issue:
145.64 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Kenneth Berlin
    President, Chief Executive Officer, Director
  • Igor Gitelman
    Chief Financial Officer, Principal Financial Officer
  • Andres Gutierrez
    Chief Medical Officer and Executive Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.